Board summary
Key figures
64,934
Registered population
58.6% aged 18–64
19.0%
Aged 65+
ICB 19.9% · England 17.9%
5.8%
Ethnic minority (non-White)
2.1% Asian · England 9.6%
2.5%
In IMD quintile 1
ICB 17.1% · England 21.0%
~1,646
Core20 residents (est.)
Resident basis; registered basis ~1,649 · see page 3
9,364
Hypertension register
+5.13% in 3 yrs · England +5.60%
451
SMI register
43% of Tonbridge and Malling's
1,091
COPD register
Reviews -6.96% in 3 yrs
Forecast to 2030
11,024
Hypertension patients, 2030
+1,660 on today
70.5%
QRISK ≥20% on statins, 2030
+5.82pp over 3 yrs
5.1%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Heart failure annual reviews trail comparators.
Annual reviews reached 57.0% versus 78.5% in England after a -6.0% three-year change (England +8.7%), which may reflect unverified recall gaps.
MMR second dose lags first dose.
At age 5, MMR dose 1 reaches 96.4% (above the 95.0% target), but dose 2 is 87.8%, an 8.6 pp same-cohort gap.
Breast screening coverage exceeds national benchmark.
Coverage is 77.2% against 69.9% in England and 71.6% in the ICB, after a +11.5% change over 2023 to 2024 (England +8.4%).
Population, age and ethnicity
Across 64,934 registered patients, children comprise 22.3% and older adults 19.0%
Across 64,934 registered patients, Malling PCN serves higher proportions of children aged 0-17 (22.3%) than Tonbridge and Malling (21.4%), NHS Kent and Medway ICB (20.7%) and England (19.6%). Patients aged 65+ make up 19.0%, matching the borough (19.0%), trailing the ICB (19.9%) and exceeding England (17.9%). Resident Census estimates (reflecting local residents rather than registered patients) show 94.2% White ethnicity (borough 93.2%, ICB 88.6%, England 81.1%), a 5.8% ethnic minority share, and 0.4% Gypsy or Irish Traveller residents (borough 0.3%, ICB 0.3%, England 0.1%). Service planning must balance paediatric demand with older-adult care.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Tonbridge and Malling local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Tonbridge and Malling LA) | 2,458 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 77.3% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.0% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Tonbridge and Malling LA) | 1,199 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Tonbridge and Malling LA) | 15.6 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is low at 2.5% but heavily concentrated in one practice
Malling PCN records a low Core20 cohort of 2.5%, against 2.4% in Tonbridge and Malling, 17.1% in NHS Kent and Medway ICB and 21.0% in England (average IMD decile 7.0). Deprivation is sharply concentrated: practice shares span 9.1 pp, led by Thornhills Medical Practice at 9.1% (estimated 1,326 patients), while Wateringbury records 1.4% and Snodland Medical Practice 0.0%. Practice estimates sum to 1,649, while resident Core20 estimates total 1,646 across different population bases. Focusing outreach at Thornhills Medical Practice rather than blanket deployment addresses the bulk of local Core20 need.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
451
SMI register
0.70% recorded prevalence
331
Learning disability register
0.51% recorded prevalence
8
Care homes, 376 beds
In the PCN catchment
8.7%
Provide unpaid care
Tonbridge and Malling, Census 2021
Severe mental illness recorded prevalence is 0.7% (451 patients; Tonbridge and Malling 0.7%, NHS Kent and Medway ICB 0.9%, England 1.0%) and learning disability is 0.5% (331 patients; borough 0.5%, ICB 0.6%, England 0.6%). Eight catchment care homes provide 376 beds, though resident registrations are unconfirmed. Lower recorded prevalence than England does not establish undiagnosed disease or under-detection, and catchment bed counts do not confirm patient registration.
Severe mental illness: physical health checks
Recorded SMI blood pressure checks fell 4.2 pp over 2023 to 2025 to 76.8% (England +4.4 pp to 83.4%), while BMI checks fell 5.3 pp to 75.0% (England +5.1 pp to 82.1%). Declining checks risk unaddressed cardiometabolic illness.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
9,364
Hypertension register
+5.13%
Register growth, 3 yrs
Tonbridge and Malling +6.16% · England +5.60%
+2.82pp
BP control, under 80
≤140/90 · −1.12pp aged 80+
+1,660
More patients by 2030
Forecast 11,024 (16.00%)
Hypertension case-finding and control
Hypertension recorded prevalence is 14.5% (9,364 patients), below Tonbridge and Malling (15.5%) and England (15.2%), giving an unadjusted benchmark scenario of +525 to +677 patients. Recent blood pressure checks reach 86.0% (England 90.0%), but treatment to target lags at 65.3% (England 70.3%). Control is 62.7% for patients aged under 80 (England 67.8%) and 76.3% for those aged 80 and over (England 81.2%), where control fell 1.4% over 2023 to 2025 (England +2.2%). Observation periods are unstated. Trailing national control may reflect treatment titration gaps, suggesting clinical reviews could help optimize regimens.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reach 56.8%, trailing Tonbridge and Malling (62.8%) and England (63.6%), alongside lower prescribing of 1,811 items per 1,000 adults aged 18+ in 2026 (England 4,100). Lower therapy reach may reflect primary prevention recall gaps.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 91,343 | £1.80 | £1.90 | £1.86 | £164,417 |
| Cardiovascular (all), 2025 | 121,612 | £4.01 | £3.57 | £3.33 | £487,664 |
In 2026, lipid-regulating drug prescribing reached 91,343 items at £1.80 per item, compared with £1.57 in Tonbridge and Malling and £1.86 in England, spending £5,481 less than at England's unit cost. Lower unit cost than England reflects favorable item spend, though prescribing reach requires review.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+4.89%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+2.78%
Asthma prevalence, PCN 3-yr % change
COPD annual review completion is 62.0% (Tonbridge and Malling 66.2%, NHS Kent and Medway ICB 72.5%, England 76.4%), after reviews fell 7.0% over 2023 to 2025 (England +2.8%). COPD prevalence is 1.7% (1,091 patients). Asthma prevalence is 6.3% (3,797 patients), with review completion at 59.1% (England 65.7%), leaving an unreviewed scale indicator of 1,554 patients. Second-hand smoking status was recorded for 72.6% of asthma patients aged 6-19 (England 78.8%). Lower review completion may indicate recall gaps, risking unmanaged respiratory symptoms.
Cancer register and children's immunisation
Cancer prevalence is 4.4% (2,831 patients; England 3.8%). In childhood immunisations, age-5 MMR1 coverage reaches 96.4%, exceeding the 95.0% target. However, MMR2 coverage drops to 87.8% across the 197-child cohort—an 8.6 pp difference, falling 7.2 pp below target—and 4-in-1 booster coverage is 86.8%. At Phoenix Medical Practice, the MMR drop is 12.5 pp. The sharp second-dose drop leaves preschool children incompletely protected.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In 2022, NHS Kent and Medway ICB recorded 55.6% of cancers with a known stage diagnosed at stage 1 or 2 (4,661 of 8,384 staged cases; England 55.3%), showing a distance of -19.4 pp to the 75.0% national ambition by 2028. Across all 13,189 registered cancers, staging coverage was 63.6% (England 67.0%), requiring 1,627 extra early-stage cases annually across the ICB to reach 75.0%. Early staging is not measured at PCN level, where Malling PCN registers 2,831 cancer patients (4.4% prevalence). Cervical screening reached 73.0% (England 66.8%), though 3-year change was -1.9% (England -1.0%). Active primary care recall is essential to prevent further screening erosion.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Maidstone and Tunbridge Wells NHS Trust met both cancer standards: 62-day referral to treatment was 87.4% (85.0% standard), ahead of Medway NHS Foundation Trust (81.6%), Dartford and Gravesham NHS Trust (63.6%), NHS Kent and Medway Integrated Care Board (75.9%) and England (71.2%). Its 28-day faster diagnosis reached 81.8% (75.0% standard; ICB 76.8%, England 79.3%). In diagnostics in Jul 2026, 6+ week waits were 0.5% for CT and 0.9% for MRI (England 9.9% and 21.4%). Local acute provider performance provides timely diagnostic access for urgent referrals.
| Pathways within standard (%) | Maidstone and Tunbridge Wells | Medway | Dartford and Gravesham | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.78 | 77.77 | 78.14 | 76.78 | 79.32 |
| 31-day treatment (96%) | 98.35 | 99.62 | 97.48 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 87.43 | 81.64 | 63.59 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Maidstone and Tunbridge Wells | Medway | Dartford and Gravesham | England |
|---|---|---|---|---|
| MRI | 0.92 | 0.68 | 0.36 | 21.40 |
| CT | 0.51 | 0.00 | 2.08 | 9.92 |
| Echocardiography | 2.57 | 36.62 | 3.90 | 28.48 |
| Colonoscopy | 19.80 | 1.88 | 0.40 | 30.83 |
| Gastroscopy | 24.03 | 3.32 | 0.00 | 29.02 |
| All 15 DM01 tests | 6.42 | 14.20 | 8.37 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In Jun 2026 (provisional), Tonbridge and Malling residents recorded 210,170 community service contacts, with 138,250 involving adults aged 65 and over, representing 65.8% of all contacts. These borough-level figures reflect community caseloads among older populations interfacing with primary care.
Practice variation and patient experience
Practice vaccination achievement spans a 41.7 pp range despite high clinical QOF scores
In 2025/26, clinical QOF achievement reached 97.3% at West Malling Group Practice and 100.0% at Phoenix Medical Practice (England 97.1%). Vaccination achievement spanned a 41.7 pp range, from 29.1% at Snodland Medical Practice to 70.8% at Phoenix Medical Practice (England 55.2%). Vaccination personalised care adjustments were 2.1% at Phoenix Medical Practice and 3.5% at West Malling Group Practice (England 4.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Wateringbury | 118 | 1.4 | 66.0% | 74.6% | 83.5% |
| Thornhills | 108 | 9.1 | 32.4% | 76.5% | 69.9% |
| Snodland Medical | 111 | 0.0 | 59.2% | 82.4% | 65.1% |
| West Malling | 142 | 0.8 | 31.6% | 80.9% | 63.7% |
| Phoenix Medical | 92 | 0.0 | 45.5% | 72.9% | 57.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Sixteen of 25 tracked measures trailed England, led by declining annual reviews
Sixteen of 25 tracked measures trailed England over 2023 to 2025. Heart failure reviews fell 6.0% (England +8.7%) to 57.0% (England 78.5%), and COPD reviews dropped 7.0% (England +2.8%) to 62.0% (England 76.4%). Mental health BMI checks fell 5.3 pp to 75.0% (England +5.1 pp), and blood pressure checks fell 4.2 pp to 76.8% (England +4.4 pp). Conversely, breast screening rose 11.5% over 2023 to 2024 (England +8.4%) to 77.2% (England 69.9%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
BMI record (SMI)
COPD reviews
Dementia register
BP check (SMI)
QRISK statin treatment
Breast screening (53-70)
BP control, under 80
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Tonbridge and Malling | Asset | PCN | Tonbridge and Malling |
|---|---|---|---|---|---|
| Care homes (catchment) | 8 (376 beds) | n/a | Schools (catchment) | 53 | n/a |
| Children's centres | 4 | 6 | Places of worship | 51 | 75 |
| Libraries | 3 | 7 | Food banks (VCS) | n/a | 1 |
| Homelessness support (VCS) | n/a | 1 | Day centres (VCS) | 3 | 4 |
| Carers support groups (VCS) | n/a | 2 | Primary schools (LA maintained) | 15 | 28 |
| Primary academies | 12 | 14 | Special schools | n/a | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension case-finding and treatment review
Hypertension prevalence is 14.5% (9,364 patients) vs 15.2% in England and 15.5% in Tonbridge and Malling (+525 to +677 benchmark scenario); control is 65.3% (England 70.3%). For discussion: practices could pair uncoded raised BP searches with pharmacist-led titration and lipid reviews (QRISK >= 20% therapy is 56.8%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Structured asthma and respiratory review recall
Asthma review completion is 59.1% vs England's 65.7% (leaving a scale indicator of 1,554 of 3,797 patients unreviewed), while COPD reviews fell 7.0% to 62.0%. For discussion: the PCN could run a standardised respiratory recall using flexible after-school or remote slots and check inhaler prescribing at review. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Combined SMI physical health check recall
On the 451-patient SMI register, annual BP checks fell 4.2 pp over 2023 to 2025 to 76.8% (England 83.4%), and BMI checks fell 5.3 pp to 75.0% (England 82.1%). For discussion: practices could introduce a single combined-check appointment, audit partial component recording, and assign named outreach leads for non-attenders. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Inclusion health community engagement (p2) | Gypsy or Irish Traveller | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension medication titration review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool MMR booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Hypertension case-finding and treatment review (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Structured asthma and respiratory review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD patients with a review in the last 12 months | Core20PLUS5 respiratory | PCN |
| Option 3 · Combined SMI physical health check recall (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
